ASH 2023 | Prognostic impact of WT1 mutations in newly diagnosed and R/R AML
Himachandana Atluri
• 9 Dec 2023
Himachandana Atluri, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, speaks on a retrospective study evaluating the prognostic impact of Wilms tumor 1 (WT1) mutations in acute myeloid leukemia (AML). In both newly diagnosed and relapsed/refractory (R/R) AML, this mutation is associated with a poor prognosis, with stem cell transplantation (SCT) being the most effective treatment strategy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
